Page last updated: 2024-08-22

gadolinium and teriflunomide

gadolinium has been researched along with teriflunomide in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Alvarez, E; Bosco, JA; Cree, BAC; Cutter, G; Fox, E; Hartung, HP; Hsu, Y; Huang, D; Lee, L; Miskin, HP; Mok, K; Power, SA; Qian, P; Robertson, D; Selmaj, K; Steinman, L; Weiss, MS; Wray, S; Wynn, D; Xu, Y	1

Trials

1 trial(s) available for gadolinium and teriflunomide

Article	Year
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. The New England journal of medicine, 2022, 08-25, Volume: 387, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Crotonates; Double-Blind Method; Gadolinium; Humans; Hydroxybutyrates; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines	2022

Article

Year

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.

The New England journal of medicine, 2022, 08-25, Volume: 387, Issue:8

Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Crotonates; Double-Blind Method; Gadolinium; Humans; Hydroxybutyrates; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines

2022